<DOC>
	<DOCNO>NCT03038022</DOCNO>
	<brief_summary>The primary objective study determine effect once-daily oral MGL-3196 percent change baseline low-density lipoprotein cholesterol ( LDL-C ) patient Heterozygous Familial Hypercholesterolemia ( HeFH ) .</brief_summary>
	<brief_title>Study MGL-3196 Patients With Heterozygous Familial Hypercholesterolemia ( HeFH )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Must willing participate study provide write informed consent ; Male female adult ≥18 year age ; Female patient child bear potential negative serum pregnancy ( beta human chorionic gonadotropin ) test breastfeeding , plan become pregnant study , agree use effective birth control ( ie , condom , diaphragm , nonhormonal intrauterine device [ IUD ] , sexual abstinence [ line patient 's current lifestyle ] ) throughout study least 1 month study completion ; hormonal contraception ( estrogens stable ≥3 month ) hormonal IUDs permit used secondary birth control measure ( eg , condom ) ; OR female patient nonchild bear potential ( ie , surgically [ bilateral oophorectomy , hysterectomy , tubal ligation ] naturally sterile [ &gt; 12 consecutive month without menses ] ) ; male patient sexual intercourse female partner child bear potential first dose study drug 1 month study completion must either surgically sterile ( confirm document azoospermia &gt; 90 day procedure ) OR agree use condom spermicide . All male patient must agree donate sperm first dose study drug 1 month study completion ; Must diagnosis HeFH genetic test meet diagnostic criterion definite familial hypercholesterolemia outline Simon Broome Register Group WHO/Dutch Lipid Network ( score &gt; 8 ) ; Must fast LDLC ≥ 2.6 mmol/L ( 100 mg/dL ) ; Must stable maximally tolerate dose ( ≥ 4 week prior screen ) approve statin ( rosuvastatin ≤ 20 mg daily , atorvastatin ≤ 80 mg daily ) , without ezetimibe . Homozygous familial hypercholesterolemia Lowdensity lipoprotein ( LDL ) plasma apheresis within 2 month prior randomization ; New York Heart Association class III IV heart failure , know leave ventricular ejection fraction &lt; 30 % ; Uncontrolled cardiac arrhythmia , include confirm QT interval correct use Fridericia 's formula ( QTcF ) &gt; 450 msec male &gt; 470 msec female screen electrocardiogram ( ECG ) assessment ; Myocardial infarction , unstable angina , percutaneous coronary intervention , coronary artery bypass graft , stroke within 3 month prior randomization ; Type 1 diabetes , newly diagnose uncontrolled type 2 diabetes ( hemoglobin A1c [ HbA1c ] &gt; 8 % ) ; History significant alcohol consumption period 3 consecutive month within 1 year prior screening ; Note : Significant alcohol consumption define average &gt; 20 g/day female patient &gt; 30 g/day male patient ; Thyroid replacement therapy ; Evidence chronic liver disease ; Hepatitis B , define presence hepatitis B surface antigen ; Hepatitis C , define presence hepatitis C virus ( HCV ) antibody ( antiHCV ) HCV ribonucleic acid ( RNA ) . Patients positive antiHCV test negative HCV RNA screen allow participate study ; Serum alanine aminotransferase ( ALT ) &gt; 1.5 × ULN ( one repeat allow ) ; Estimated glomerular filtration rate &lt; 60 mL/min ; Creatine kinase &gt; 3 × ULN ( one repeat allow ) ; History biliary diversion ; Positive human immunodeficiency virus infection ; History malignant hypertension ; Systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg screen randomization confirm unscheduled visit ; Triglycerides &gt; 5.7 mmol/L ( 500 mg/dL ) screening confirm repeat assessment ; Active , serious medical disease likely life expectancy &lt; 2 year ; Active substance abuse , include inhale injection drug within year prior screening ; Participation investigational new drug trial within 30 day prior randomization ; Any condition , opinion Investigator , would impede compliance , hind completion study , compromise wellbeing patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>